{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:12:11Z","timestamp":1778285531721,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacadv.2025.101800","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:16:55Z","timestamp":1750864615000},"page":"101800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients"],"prefix":"10.1016","volume":"4","author":[{"given":"Andrew J.","family":"Sauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joycie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuxuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Valenzuela Ripoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoonje","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-4852","authenticated-orcid":false,"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-7623","authenticated-orcid":false,"given":"Senthil","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl L.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany A.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Dahlb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101800_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2021.08.039","article-title":"Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system","volume":"334","author":"Mattisson","year":"2021","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.jacadv.2025.101800_bib2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.045323","article-title":"Reduced apolipoprotein M and adverse outcomes across the spectrum of human heart failure","volume":"141","author":"Chirinos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101800_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.846990","article-title":"HDL composition, heart failure, and its comorbidities","volume":"9","author":"Diab","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101800_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacbts.2020.11.011","article-title":"Quantitative proteomic analysis of diabetes mellitus in heart failure with preserved ejection fraction","volume":"6","author":"Hanff","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"23","key":"10.1016\/j.jacadv.2025.101800_bib5","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.jacadv.2025.101800_bib6","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.M009993200","article-title":"Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein\/phosphoinositide 3-kinase pathway in endothelial cells","volume":"276","author":"Morales-Ruiz","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101800_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2011.11.031","article-title":"Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL","volume":"221","author":"Els\u00f8e","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101800_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacbts.2022.09.010","article-title":"Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury","volume":"8","author":"Guo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101800_bib9","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1096\/fj.201801748R","article-title":"Apolipoprotein M suppresses the phenotypes of IgA nephropathy in hyper-IgA mice","volume":"33","author":"Kurano","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.jacadv.2025.101800_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.atherosclerosis.2018.06.815","article-title":"Apolipoprotein M in patients with chronic kidney disease","volume":"275","author":"S\u00f8rensen","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101800_bib11","article-title":"Dapagliflozin improves endothelial integrity and hemodynamics in endotoxin treated mice through an apolipoprotein M dependent pathway","author":"Ripoll","year":"2022","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101800_bib12","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (Low-Density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101800_bib13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jacadv.2025.101800_bib14","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jacadv.2025.101800_bib15","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional Status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101800_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101800_bib17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101800_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.jacadv.2025.101800_bib19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacadv.2025.101800_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG outcome trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101800_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/eurheartj\/ehac528","article-title":"Albuminuria as a marker of systemic congestion in patients with heart failure","volume":"44","author":"Boorsma","year":"2023","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101800_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101800_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.devcel.2020.05.024","article-title":"Aging suppresses sphingosine-1-phosphate chaperone ApoM in circulation resulting in maladaptive organ repair","volume":"53","author":"Ding","year":"2020","journal-title":"Dev Cell"},{"issue":"15","key":"10.1016\/j.jacadv.2025.101800_bib24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101800_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101800_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:27:41Z","timestamp":1778282861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25002182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2772963X25002182"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101800","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101800"}}